Convalescent Plasma for COVID-19 / Del Rosario University - LARVOL DELTA

Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. (PubMed, BMC Infect Dis) - P2/3 | "CP was not associated with viral load reduction, despite the early increase in IgG anti-SARS-CoV-2 antibodies. However, CP is safe and could be a therapeutic option to reduce the hospital length of stay. Trial registration NCT04332835."

Clinical • Journal • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. (PubMed, BMC Infect Dis) - "Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care."

Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study (clinicaltrials.gov) - P2/3; N=92; Completed; Sponsor: Universidad del Rosario; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (clinicaltrials.gov) - P2/3; N=90; Recruiting; Sponsor: Universidad del Rosario; Not yet recruiting ➔ Recruiting; Initiation date: May 2020 ➔ Aug 2020

Clinical • Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Pilot Study (clinicaltrials.gov) - P2; N=10; Completed; Sponsor: Universidad del Rosario; Not yet recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Jul 2020

Clinical • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (clinicaltrials.gov) - P2/3; N=80; Not yet recruiting; Sponsor: Universidad del Rosario

Clinical • New P2/3 trial

CP-COVID-19: Convalescent Plasma for Patients With COVID-19: A Pilot Study (clinicaltrials.gov) - P2; N=10; Not yet recruiting; Sponsor: Universidad del Rosario

Clinical • New P2 trial